CCM
ONCY

Chiron Capital Management’s Oncolytics Biotech ONCY Stock Holding History

Chiron Capital Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,200
Closed -$21K – 114
2021
Q3 		$21K Hold
10,200
– – 0.02% 99
2021
Q2 		$28K Buy
10,200
+200
+2% +$613 0.02% 78
2021
Q1 		$38K Buy
+10,000
New +$29.8K 0.03% 71
2020
Q4 		– Sell
-3,500
Closed -$6K – 330
2020
Q3 		$6K Buy
+3,500
New +$6.42K ﹤0.01% 349

Other funds holding ONCY

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Chiron Capital Management's ONCY Position: Q4 2021 in Review

Chiron Capital Management sold out of Oncolytics Biotech (ONCY) in Q4 2021, closing a stake of 10,200 shares — an estimated $21K sold.

Chiron Capital Management first reported a position in ONCY in Q3 2020 and held it in 4 quarters. The position peaked at $38K in Q1 2021. 45 funds tracked by Wall St. Rank hold ONCY as of Q4 2021.

  • Chiron Capital Management reported no remaining Oncolytics Biotech position as of Q4 2021 after selling out during the quarter.
  • Chiron Capital Management sold 10,200 Oncolytics Biotech shares in Q4 2021, an estimated $21K.
  • Chiron Capital Management first reported a position in Oncolytics Biotech in Q3 2020 and held it in 4 quarters.
  • Chiron Capital Management's Oncolytics Biotech position peaked at $38K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2021.

Based on Chiron Capital Management's 13F filing for Q4 2021, filed 18 Jan 2022.